Close

Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. announced that the companies have newly launched “Micatrio®Combination Tablets,” a combination drug of “Micardis® Tablets” (AT1 receptor blocker [ARB]), long-acting calcium channel blocker (CCB) amlodipine besylate and the thiazide diuretic hydrochlorothiazide (HCTZ).

More Articles ...

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok